ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay

Zhang, Yunfeng; Wu, Qian; Xu, Linhao; Wang, Hong; Liu, Xin; Li, Sihui; Hu, Tianliang; Liu, Yanying; Peng, Quanzhou; Chen, Zhiwei*; Wu, Xianrui*; Fan, Jian-Bing*南方医科大学; 中山大学; 6
Clinical Epigenetics2021-4-23DOI: 10.1186/s13148-021-01076-8
17被引7阅读
引用收藏
分享

摘要

Background Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. Early detection of CRC can significantly reduce its mortality rate. Current method of CRC diagnosis relies on the invasive endoscopy. Non-invasive assays including fecal occult blood testing (FOBT) and fecal immunological test (FIT) are compromised by low sensitivity and specificity, especially at early stages. Thus, a non-invasive and accurate approach for CRC screening would be highly desirable. Results A new qPCR-based assay combining the simultaneous detection of the DNA methylation status of ten candidate genes was used to examine plasma samples from 56 normal controls, 6 hyperplastic polys, 9 non-advanced adenomas (NAAs), 22 advanced adenomas (AAs) and 175 CRC patients, using 10 ng of cfDNA. We further built a logistic regression model for CRC diagnosis. We tested ten candidate methylation markers including twist1, vav3-as1, fbn1, c9orf50, sfmbt2, kcnq5, fam72c, itga4, kcnj12 and znf132. All markers showed moderate diagnostic performance with AUCs ranging from 0.726 to 0.815. Moreover, a 4-marker model, comprised of two previously reported markers (c9orf50 and twist1) and two novel ones (kcnj12 and znf132), demonstrated high performance for detecting colorectal cancer in an independent validation set (N = 69) with an overall AUC of 0.911 [95% confidence interval (CI) 0.834-0.988], sensitivity of 0.800 [95% CI 0.667-0.933] and specificity of 0.971 [95% CI 0.914-1.000]. The stage-stratified sensitivity of the model was 0.455 [95% CI 0.227-0.682], 0.667 [95% CI 0.289-1.000], 0.800 [95% CI 0.449-1.000], 0.800 [95% CI 0.449-1.000] and 0.842 [95% CI 0.678-1.000] for advanced adenoma and CRC stage I-IV, respectively. Conclusion kcnj12 and znf132 are two novel methylation biomarkers for CRC diagnosis. The 4-marker methylation model provides a new non-invasive choice for CRC screening and interception.

学科与关键词

关键词
Liquid biopsyMethylation biomarkerColorectal cancer
相关
加载中…
  • A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer
    Wu, Xianrui; Zhang, Yunfeng; Hu, Tuo; He, Xiaowen; Zou, Yifeng; Deng, Qiling; Ke, Jia; Lian, Lei; He, Xiaosheng; Zhao, Dezhi; Cai, Xuyu; Chen, Zhiwei; Wu, Xiaojian; Fan, Jian-Bing*; Gao, Feng*; Lan, Ping*Molecular Oncology, 2021, 15(10): 2702-2714.被引 29
  • Discovery and validation of tissue-specific DNA methylation as noninvasive diagnostic markers for colorectal cancer
    Li, Dapeng; Zhang, Lei; Fu, Jinming; Huang, Hao; Liu, Yanlong; Zhu, Lin; Sun, Hongru; Sun, Simin; Zhang, Ding; Tian, Tian; Wang, Fan; Hu, Fulan; Peng, Xiaolin; Li, Gairui; Zhao, Liyuan; Zheng, Ting; Wang, Xuan; Cui, Binbin*; Zhao, Yashuang*Clinical Epigenetics, 2022, 14(1): 102.被引 3
  • A novel screening method of DNA methylation biomarkers helps to improve the detection of colorectal cancer and precancerous lesions
    Li, Yuan; Li, Bin; Jiang, Rou; Liao, Leen; Zheng, Chunting; Yuan, Jie; Zeng, Liuhong; Hu, Kunling; Zhang, Yuyu; Mei, Weijian; Hong, Zhigang; Xiao, Binyi; Kong, Lingheng; Han, Kai; Tang, Jinghua; Jiang, Wu; Pan, Zhizhong*; Zhang, Shenyan*; Ding, Peirong*Cancer Medicine, 2023, 12(21): 20626-20638.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Epigenetics
发表日期
2021-04-23
卷期
第 13 卷, 第 1 期
页码
90
DOI
10.1186/s13148-021-01076-8
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Science and Technology Planning Project of Guangdong Province, China [2017B020226005]; Scheme of Guangzhou for Leading Team in Innovation [201909010010]; Scheme of Guangzhou for Leading Talents in Innovation and Entrepreneurship [2016007]; Scheme of Guangzhou Economic and Technological Development District for Leading Talents in Innovation and Entrepreneurship [2017-L152]; National Key R&D Program of China [2017YFC1308800]; National Natural Science Foundation of China [81870383]; Clinical Innovation Research Program of Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory) [2018GZR0201005]; Science and Technology Planning Project of Guangzhou City [201804010014, 201803040019]; Sun Yatsen University 5010 Project [2010012]

作者

  • Z

    Zhang, Yunfeng (第一作者)

    6 · sun yat sen univ

  • W

    Wu, Qian

    6 · sun yat sen univ

查看全部 12 位作者收起作者
  • X

    Xu, Linhao

  • W

    Wang, Hong

  • L

    Liu, Xin

  • L

    Li, Sihui

  • H

    Hu, Tianliang

  • L

    Liu, Yanying

  • P

    Peng, Quanzhou

    southern med univ

  • C

    Chen, Zhiwei (通讯)

  • W

    Wu, Xianrui (通讯)

    6 · sun yat sen univ

  • F

    Fan, Jian-Bing (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417